. Stocks rise, Dow climbs more than 100 points on Merck's promising Covid treatment - Trade FX, CFD, Stocks, BTC, Indices, Gold & Oil - 1:1000 Leverage & Bonus - CSFX

Stocks rise, Dow climbs more than 100 points on Merck’s promising Covid treatment

Stocks rise, Dow climbs more than 100 points on Merck’s promising Covid treatment

01 Oct 2021

U.S. stocks pushed higher on Friday as news of a new oral treatment for Covid-19 boosted shares of companies tied to the economic recovery.

The Dow Jones Industrial Average added 190 points, or about 0.6%. The S&P 500 rose 0.3%, while the tech-heavy Nasdaq Composite hovered just below the flatline and was on track for its sixth-straight losing session.

Shares of Dow member Merck jumped 7% after the drug maker and Ridgeback Biotherapeutics said their oral antiviral treatment for Covid-19 reduced the risk of hospitalization or death by 50% for patients with mild or moderate cases. The companies plan to seek emergency authorization for the treatment.

The new drug from Merck appeared to boost travel stocks. Shares of Royal Caribbean and Las Vegas Sands added 3% and 2%, respectively, in early trading. Southwest Airlines led a gain in airline stocks after JPMorgan upgraded the stock and said most of the group was worth buying for a trade. Bank stocks rose as well, helping the Dow outperform.

“We have seen this rotation back to the so-called reopening plays and the more cyclical areas, which I think makes a lot of sense over the next couple of weeks as we think about the Covid trends improving, with the cases falling from last month’s peak, and the news about the Merck pill appears promising,” said Angelo Kourkafas, an investment strategist at Edward Jones.

Vaccine stocks, including Moderna, dipped in early trading following the Merck news.

The 10-year Treasury yield fell back below 1.50% in early trading. A jump in rates to end September knocked tech stocks.

The market just capped a tumultuous September as inflation fears, slowing growth and rising rates kept investors on edge. The S&P 500 finished the month down 4.8%, breaking a seven-month winning streak. The Dow and the Nasdaq Composite fell 4.3% and 5.3%, respectively, suffering their worst months of the year.

“A combination of slowing growth, less accommodative monetary policy, China headwinds, fading fiscal stimulus, and nagging supply chain bottlenecks all conspired to weigh on investor sentiment as we head into fall and 4Q21,” Chris Hussey, a managing director at Goldman Sachs, said in a note.

Ten of the 11 S&P 500 sectors suffered losses in September, led to the downside by a 7.4% monthly drop in materials stocks. Energy is the best performer of the month, gaining more than 9%.

The S&P ended Thursday 5.2% below its all-time high reached in early September, the first 5% pullback of 2021. The broad equity benchmark is still up nearly 15% on the year however.

Stock picks and investing trends from CNBC Pro:

On the data front, personal income rose 0.2% in August, in line with expectations. The price index for core personal consumption expenditures was up 3.6% year over year, slightly ahead of the estimate of 3.5% from economists surveyed by Dow Jones.

“As we wrap up the third quarter and look ahead, investors will likely need to remain nimble as the economic recovery continues in a zig zag,” said Mike Loewengart, managing director of investment strategy at E-Trade Financial.

While October is known for notable market crashes, it typically is the start of a better seasonal period for stocks. The S&P 500 averages a 0.8% gain in October, according to the Stock Trader’s Almanac. Stocks average a 1.6% increase and 1.5% rise in November and December, respectively, according to the almanac.

Congress was poised to prevent a government shutdown Thursday. The Senate and House both passed a short-term appropriations bill that would keep the government running through Dec. 3 and sent it to President Joe Biden to sign.